Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update

Kezar Life Sciences, Inc. (NASDAQ:KZR) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,570,000 shares, a growth of 5.6% from the March 15th total of 3,380,000 shares. Based on an average daily trading volume, of 717,500 shares, the short-interest ratio is currently 5.0 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Kezar Life Sciences in a report on Friday, March 15th.

Institutional Investors Weigh In On Kezar Life Sciences

A number of institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its stake in Kezar Life Sciences by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 140,148 shares of the company’s stock worth $987,000 after purchasing an additional 1,608 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Kezar Life Sciences by 11.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 20,633 shares of the company’s stock worth $145,000 after purchasing an additional 2,040 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Kezar Life Sciences by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 277,928 shares of the company’s stock valued at $4,619,000 after purchasing an additional 2,130 shares in the last quarter. American International Group Inc. boosted its position in Kezar Life Sciences by 15.8% during the second quarter. American International Group Inc. now owns 21,768 shares of the company’s stock worth $180,000 after purchasing an additional 2,968 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Kezar Life Sciences by 88.9% during the third quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company’s stock valued at $58,000 after acquiring an additional 3,190 shares during the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Trading Up 4.3 %

Shares of KZR stock opened at $0.82 on Thursday. Kezar Life Sciences has a 12-month low of $0.67 and a 12-month high of $3.13. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $0.90 and a two-hundred day moving average price of $0.89. The firm has a market cap of $59.45 million, a P/E ratio of -0.58 and a beta of 0.47.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Thursday, March 14th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Equities analysts anticipate that Kezar Life Sciences will post -1.26 EPS for the current fiscal year.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.